Why Choose Sitakreios

Advanced DPP-4 Innovation for Diabetes Management

Discover the clinical advantages of Sitakreios DPP-4 inhibitor range for effective Type 2 diabetes mellitus treatment

Advanced DPP-4 Innovation

Advanced DPP-4 inhibition mechanism for superior glucose-dependent insulin regulation and enhanced pancreatic function in Type 2 diabetes mellitus patients.

Weight Neutral Therapy

Weight-neutral therapy with low risk of hypoglycemia and excellent patient compliance for long-term diabetes management and improved quality of life.

Modern Pharmaceutical Technology

Cutting-edge pharmaceutical technology with precision manufacturing and comprehensive quality assurance following WHO-GMP standards.

Complete Range

Sitakreios Product Portfolio

Comprehensive DPP-4 inhibitor solutions tailored for different patient needs and diabetes management protocols

Sitakreios-DM Triple Combination Therapy for Type 2 Diabetes - Sitagliptin, Dapagliflozin, Metformin

Sitakreios-DM

Triple Combination Therapy

Comprehensive triple therapy combining sitagliptin, dapagliflozin, and metformin for optimal diabetes management and superior glycemic control.

Sitagliptin Dapagliflozin Metformin
Sitakreios-100 Enhanced Strength DPP-4 Inhibitor 100mg for Intensive Diabetes Management

Sitakreios-100

Enhanced Strength DPP-4 Inhibitor

High-strength sitagliptin 100mg formulation for patients requiring intensive diabetes management and superior glucose control.

Sitagliptin 100mg Enhanced Formula
Sitakreios

Sitakreios

Sitagliptin Monotherapy

Pure DPP-4 inhibitor providing targeted glucose-dependent insulin regulation for effective diabetes management.

Sitagliptin 100mg Once Daily
Sitakreios-D

Sitakreios-D

Dapagliflozin Combination

Advanced combination of sitagliptin with dapagliflozin for comprehensive diabetes management with cardiovascular benefits.

Sitagliptin + Dapagliflozin Cardio Benefits
Sitakreios-M

Sitakreios-M

Combination Therapy

Fixed dose combination of sitagliptin and metformin for comprehensive dual-mechanism diabetes control.

Sitagliptin Metformin Dual Action
Scientific Excellence

Advanced DPP-4 Technology

Our Sitakreios range employs cutting-edge DPP-4 inhibition technology to deliver optimal therapeutic outcomes with enhanced safety and patient compliance.

DPP-4 Selective Inhibition

Selective inhibition of DPP-4 enzyme enhances incretin hormone levels for glucose-dependent insulin secretion.

Cardiovascular Safety

Proven cardiovascular safety profile with neutral to beneficial effects on heart health and weight management.

Sustained Efficacy

Long-lasting glucose control with minimal risk of hypoglycemia and excellent long-term safety profile.

Key Active Ingredients

Sitagliptin
DPP-4 Inhibitor
50-100mg
Metformin HCl
Insulin Sensitizer
500-1000mg
Dapagliflozin
SGLT-2 Inhibitor
5-10mg
Clinical Efficacy

Up to 1.5% reduction in HbA1c levels with minimal hypoglycemia risk and excellent cardiovascular safety

Clinical Excellence

Proven Clinical Benefits

97%
Patient Satisfaction

High patient compliance and satisfaction rates with minimal side effects

1.5%
HbA1c Reduction

Significant improvement in glycemic control with DPP-4 inhibition

Low
Hypoglycemia Risk

Minimal risk of hypoglycemia due to glucose-dependent mechanism

98%
Safety Profile

Excellent safety and tolerability in long-term clinical studies

Diabetes Management

Type 2 Diabetes Mellitus Benefits of Sitakreios Tablet

In Type 2 Diabetes Mellitus

Type 2 diabetes mellitus is a long-term condition where the body either does not produce enough insulin or does not use it effectively, leading to high blood sugar levels.

How Sitakreios 50mg Tablet Helps:
  • Increases insulin release from pancreatic beta cells
  • Decreases sugar production in the liver
  • Improves overall blood sugar control
  • Reduces diabetes-related complications

This improves overall blood sugar control and reduces diabetes-related complications.

Advanced Mechanism

1
DPP-4 Inhibition
Blocks DPP-4 enzyme action
2
Incretin Enhancement
Increases GLP-1 and GIP levels
3
Glucose Control
Reduces blood sugar levels
Frequently Asked Questions

Everything About Sitakreios DPP-4 Inhibitor

What is Sitakreios and how does it work for Type 2 diabetes?

Sitakreios is an advanced DPP-4 inhibitor containing sitagliptin that helps manage Type 2 diabetes mellitus. It works by blocking the DPP-4 enzyme, which increases incretin hormone levels (GLP-1 and GIP), leading to glucose-dependent insulin secretion and decreased glucagon release.

What are the available formulations of Sitakreios?

Sitakreios is available in multiple formulations: Sitakreios 50mg and 100mg (monotherapy), Sitakreios-M (with Metformin), Sitakreios-D (with Dapagliflozin), and Sitakreios-DM (triple combination with Metformin and Dapagliflozin).

What are the benefits of Sitakreios over other diabetes medications?

Sitakreios offers weight neutrality, low hypoglycemia risk, once-daily dosing, excellent cardiovascular safety profile, and can be used as monotherapy or in combination with other antidiabetic agents for comprehensive diabetes management.

Is Sitakreios suitable for all Type 2 diabetes patients?

Sitakreios is indicated for Type 2 diabetes mellitus patients as monotherapy or combination therapy. However, it should be used under medical supervision, and dosage adjustments may be needed in patients with kidney impairment. Consult your healthcare provider for personalized treatment recommendations.

Ready to Partner with Kreios Pharma?

Join hands with us to bring advanced DPP-4 inhibitor solutions to patients worldwide. Contact our team for partnership opportunities, product inquiries, or technical support.